Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation

INTRODUCTION: Natalizumab (NTZ) is an effective drug for the treatment of relapsing‐remitting multiple sclerosis. In some patients discontinuation is mandatory due to the risk of progressive multifocal leukoencephalopathy. However, severe clinical and radiological worsening has been described after...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Brain Behav
Main Authors: González‐Suarez, Inés, Rodríguez de Antonio, Luis, Orviz, Aida, Moreno‐García, Sara, Valle‐Arcos, María D., Matias‐Guiu, Jordi A., Valencia, Cristina, Jorquera Moya, Manuela, Oreja‐Guevara, Celia
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5390845/
https://ncbi.nlm.nih.gov/pubmed/28413713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/brb3.671
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados